Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × Radiosurgery × Clear all

Phase

Status

Sponsor Class

OTHER 8 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Brain Neoplasms 3 Neoplasms 2 Neoplasm Metastasis 2 Melanoma 2 Glioblastoma 2 Colorectal Neoplasms 2 Recurrence 1 Prostate Adenocarcinoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Liver Neoplasms 1 Gliosarcoma 1 Glioma 1 Central Nervous System Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Merkel Cell 1 Brain Diseases 1 Adenocarcinoma 1

Interventions

Dexamethasone 46 Cyclophosphamide 28 Lenalidomide 27 pomalidomide 24 Rituximab 23 venetoclax 22 fludarabine 21 Bortezomib 20 Paclitaxel 18 Gemcitabine 18 carfilzomib 16 Carboplatin 15 pembrolizumab 14 Cisplatin 14 daratumumab 13 Docetaxel 12 Calcium Dobesilate 12 Cytarabine 11 Azacitidine 11 obinutuzumab 10 Nivolumab 10 Bevacizumab 10 tisagenlecleucel 9 ibrutinib 9 durvalumab 8 blinatumomab 8 Injections 8 Cetuximab 8 zanubrutinib 7 selinexor 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05900908 2025-04-10

PATHWAyS

GT Medical Technologies, Inc.

Phase 4 Withdrawn

Glioblastoma, Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡